OBJECTIVES: To determine if cardiovascular (CV) drugs are associated with an increased risk of colon cancer (CC) & if the risk for any individual agent differs from risk of the therapeutic class overall. METHODS: A population-based case control study was conducted using HealthCore Integrated Research Database (HIRD^SM), a US commercial insurance claims database.  Incident cases of CC were defined as patients, ≥18 years at diagnosis, with 1st CC diagnostic claim between Jan 1, 2001 to Jan 30, 2011. Each case was matched to 1 eligible control based on: no diagnosis of CC during study period, actively enrolled at index date of the case, matched to cases by length of pre-index enrollment (same or greater), gender & age.  Exposure to CV drug was defined as at least 1 claim during risk period. Conditional logistic regression was used to calculate adjusted Odds Ratios (OR). Sensitivity analysis was conducted where minimum CV drug exposure (12 months) was required. RESULTS: